ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Hoffmann-La Roche and Beijing Biotech side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Hoffmann-La RocheBeijing Biotech
studies on the registry2,74432
open to participants now11532
phase 3 studies under way950
reach primary completion within a year7731
programswith a study of their own in two years80+25 named only40

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseHoffmann-La RocheBeijing Biotech
Phase 1

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. Anti-CDH17 Antibody-drug Conjugate HS-20110phase 1

and 28 more — sign in to see them all

41%

Beijing Biotech: 1 of its 40 programs at phase 1

  1. ETB-DualNK-01phase 1
3%
Phase 2

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%

Beijing Biotech: 39 of its 40 programs at phase 2

  1. Cyclophosphamidephase 2
  2. fludarabinephase 2
  3. Dual-target CAR-NK cellsphase 2
  4. ebnk-1822h2 dual-target cldn18.2phase 2
  5. Lymphodepleting chemotherapyphase 2

and 34 more — sign in to see them all

98%
Phase 3

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%
00%
Approved, new studies

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Hoffmann-La Roche28 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. cevostamabphase 3 · Nov 18 · NCT05646836
  2. emicizumabapproved, new study · Nov 19 · NCT05181618
  3. nivegacetorphase 2 · Nov 19 · NCT06402838
  4. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 1 program whose next study reaches primary completion

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
Beijing Biotech40 readouts · 0 phase 3···

Beijing Biotech, Feb ’27: 11 programs whose next study reaches primary completion

  1. Dual-target CAR-NK cellsphase 2 · Feb 14 · NCT07467863
  2. Dual-target CAR-NK cells (EB-DT-CAR-NK)phase 2 · Feb 14 · NCT07486089
  3. EB-DART-NK01phase 2 · Feb 14 · NCT07744256
  4. EB-DART-NK01 (DLL3/CD56 CAR-NK cells)phase 2 · Feb 14 · NCT07480213
  5. EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)phase 2 · Feb 14 · NCT07480928

and 6 more — sign in to see them all

Beijing Biotech, Mar ’27: 21 programs whose next study reaches primary completion

  1. Autologous Anti-CD19 CAR-expressing T Lymphocytesphase 2 · Mar 14 · NCT07523542
  2. Autologous BCMA/CD19 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555
  3. Autologous BCMA/CD38 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555
  4. Autologous BCMA/GPRC5D dual-target CAR-Tphase 2 · Mar 14 · NCT07523555
  5. Autologous CD19/CD20 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555

and 16 more — sign in to see them all

Beijing Biotech, Apr ’27: 3 programs whose next study reaches primary completion

  1. Autologous dual-target CAR-T cells selected from the predefined target library.phase 2 · Apr 14 · NCT07523529
  2. eb-701phase 2 · Apr 14 · NCT07551349
  3. EB-701/CA9-NKphase 2 · Apr 14 · NCT07551349
·

Beijing Biotech, Jun ’27: 5 programs whose next study reaches primary completion

  1. AP 1903 reagentphase 2 · Jun 14 · NCT07598955
  2. EB-CAR30-NKphase 2 · Jun 14 · NCT07598955
  3. EB-CAR5-NKphase 2 · Jun 14 · NCT07598955
  4. EB-CARMSLN-NKphase 2 · Jun 14 · NCT07598955
  5. EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cellsphase 2 · Jun 14 · NCT07627698
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Beijing Biotech

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 14 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionHoffmann-La RocheBeijing Biotech
Neoplasmsboth · compare here

Hoffmann-La Roche in Neoplasms: 4 programs

  1. inavolisibphase 3
  2. lorlatinibphase 1
  3. Pan-RAS Inhibitor RG6505phase 1
  4. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Neoplasms in search

Beijing Biotech in Neoplasms: 4 programs

  1. Lymphodepleting chemotherapyphase 2
  2. Cytokine supportphase 2
  3. EB-PT-CAR-NK-Dphase 2
  4. EB-PT-CAR-NK-Sphase 2

Their studies: Beijing Biotech’s studies of Neoplasms in search

Breast Neoplasmsboth · compare here

Hoffmann-La Roche in Breast Neoplasms: 6 programs

  1. inavolisibphase 3
  2. giredestrantphase 3
  3. bizrolertinibphase 3
  4. vustanaciclibphase 2
  5. GDC-0587phase 1

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Breast Neoplasms in search

Beijing Biotech in Breast Neoplasms: 1 program

  1. Cyclophosphamidephase 2

Their studies: Beijing Biotech’s studies of Breast Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

Beijing Biotech in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Cyclophosphamidephase 2
  2. Dual-target CAR-NK cellsphase 2

Their studies: Beijing Biotech’s studies of Carcinoma, Non-Small-Cell Lung in search

Colorectal Neoplasmsboth · compare here

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

Beijing Biotech in Colorectal Neoplasms: 1 program

  1. EB-DUO-CAR-NK-CEA/GCCphase 2

Their studies: Beijing Biotech’s studies of Colorectal Neoplasms in search

Multiple Myelomaboth · compare here

Hoffmann-La Roche in Multiple Myeloma: 4 programs

  1. cevostamabphase 3
  2. hyaluronidase (human recombinant)phase 2
  3. RO7851624phase 1
  4. RO7875913phase 1

Their studies: Hoffmann-La Roche’s studies of Multiple Myeloma in search

Beijing Biotech in Multiple Myeloma: 2 programs

  1. Cyclophosphamidephase 2
  2. fludarabinephase 2

Their studies: Beijing Biotech’s studies of Multiple Myeloma in search

Small Cell Lung Carcinomaboth · compare here
Neoplasm Metastasisboth · compare here

Hoffmann-La Roche in Neoplasm Metastasis: 2 programs

  1. inavolisibphase 3
  2. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Neoplasm Metastasis in search

Prostatic Neoplasmsboth · compare here

Hoffmann-La Roche in Prostatic Neoplasms: 3 programs

  1. inavolisibphase 3
  2. GDC-1261phase 2
  3. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Prostatic Neoplasms in search

Beijing Biotech in Prostatic Neoplasms: 2 programs

  1. AP 1903 reagentphase 2
  2. ETB-DualNK-01phase 1

Their studies: Beijing Biotech’s studies of Prostatic Neoplasms in search

Leukemia, Lymphocytic, Chronic, B-Cellboth · compare here

Hoffmann-La Roche in Leukemia, Lymphocytic, Chronic, B-Cell: 2 programs

  1. mosunetuzumabphase 3
  2. bexobrutidegno phase

Their studies: Hoffmann-La Roche’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Beijing Biotech in Leukemia, Lymphocytic, Chronic, B-Cell: 2 programs

  1. Cyclophosphamidephase 2
  2. fludarabinephase 2

Their studies: Beijing Biotech’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Lupus Nephritisboth · compare here

Hoffmann-La Roche in Lupus Nephritis: 2 programs

  1. mosunetuzumabphase 3
  2. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Lupus Nephritis in search

Lymphoma, Non-Hodgkinboth · compare here

Hoffmann-La Roche in Lymphoma, Non-Hodgkin: 2 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Non-Hodgkin in search

Beijing Biotech in Lymphoma, Non-Hodgkin: 1 program

  1. fludarabinephase 2

Their studies: Beijing Biotech’s studies of Lymphoma, Non-Hodgkin in search

Primary Immunodeficiency Diseasesboth · compare here

Hoffmann-La Roche in Primary Immunodeficiency Diseases: 2 programs

  1. hyaluronidase (human recombinant)phase 2
  2. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Primary Immunodeficiency Diseases in search

Beijing Biotech in Primary Immunodeficiency Diseases: 1 program

  1. AP 1903 reagentphase 2

Their studies: Beijing Biotech’s studies of Primary Immunodeficiency Diseases in search

Show all 14

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Hoffmann-La Roche 40 of 80 · Beijing Biotech 1 of 40 programs (20 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Hoffmann-La Roche: 25).